Literature DB >> 18047775

Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials.

Matthew E Falagas1, Konstantinos Z Vardakas, George Samonis.   

Abstract

BACKGROUND: [corrected] Neutropenia is a common complication of intensive chemotherapy in patients with solid organ or hematologic malignancies that is associated with a high risk for life-threatening infections. Many interventions have been employed in order to limit the incidence of these infections or to treat them when the prophylactic measures fail. SCOPE: The commonest characteristic of the randomized controlled trials (RCTs) conducted on this issue was the small sample size. In addition, if RCTs studying the prophylactic interventions were excluded, the aim of most of the rest of relevant RCTs was to prove the equal effectiveness of the tested interventions in terms of treatment success. We searched PubMed and Cochrane database to identify meta-analyses of RCTs in the field of febrile neutropenia.
RESULTS: The most prominent findings of these meta-analyses were the promising effect, although based on open label RCTs, of antimicrobial prophylaxis with fluoroquinolones on the mortality of all neutropenic patients and the beneficial effect of antifungal prophylaxis on mortality of neutropenic patients with allogeneic hematopoetic stem cell transplantation. Another noteworthy finding was the higher mortality associated with empiric cefepime treatment when compared with other beta-lactams. In other cases, the findings of the published meta-analyses either confirmed or consolidated the results of individual RCTs.
CONCLUSION: Meta-analyses are very useful for obtaining a better overview and to provide some general qualitative and quantitative conclusions, but are not always a substitute for appropriately powered, well-designed RCTs. In addition, the reported findings should be interpreted with caution taking into account the limitations of various methodological aspects of meta-analysis in general, as well as the limitations of the individual meta-analyses in this field.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18047775     DOI: 10.1185/030079908x253816

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

1.  Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design.

Authors:  Konstantinos Z Vardakas; Michael N Mavros; Nikolaos Roussos; Matthew E Falagas
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

2.  [Requirements for hygiene in the medical care of immunocompromised patients. Recommendations from the Committee for Hospital Hygiene and Infection Prevention at the Robert Koch Institute (RKI)].

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2010-04       Impact factor: 1.513

3.  Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.

Authors:  Mark T Drayson; Stella Bowcock; Tim Planche; Gulnaz Iqbal; Guy Pratt; Kwee Yong; Jill Wood; Kerry Raynes; Helen Higgins; Bryony Dawkins; David Meads; Claire T Hulme; Irene Monahan; Kamaraj Karunanithi; Helen Dignum; Edward Belsham; Jeff Neilson; Beth Harrison; Anand Lokare; Gavin Campbell; Michael Hamblin; Peter Hawkey; Anna C Whittaker; Eric Low; Janet A Dunn
Journal:  Lancet Oncol       Date:  2019-10-23       Impact factor: 41.316

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.